Latest Breaking News On - Therapy designation - Page 12 : comparemela.com

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

The Scleroderma Research Foundation Announces the Launch of the CONQUEST Trial Platform and IND Clearance

/PRNewswire/ The Scleroderma Research Foundation (SRF), the nation s largest non-profit funder of scleroderma research, today announced that the FDA has.

FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results

– If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure – – Interim analysis results from first-of-its-kind Phase III.

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study.